株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ADC Therapeutics Sarl の製品パイプライン分析

ADC Therapeutics SA - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 318950
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.95円で換算しております。
Back to Top
ADC Therapeutics Sarl の製品パイプライン分析 ADC Therapeutics SA - Product Pipeline Review - 2016
出版日: 2016年11月16日 ページ情報: 英文 34 Pages
概要

ADC Therapeutics Sarl はスイスに本社を持つ創薬企業です。乳癌、前立腺癌、腎がん、血液がんといった主要な癌を標的としたADCの開発に注力しています。Spirogen Limited、Cancer Research Technologyとの戦略的提携により研究開発を進めています。

当レポートでは、ADC Therapeutics Sarl における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

ADC Therapeutics Sarl の基本情報

  • ADC Therapeutics Sarl の概要
  • 主要情報
  • 企業情報

ADC Therapeutics Sarl :R&Dの概要

  • 主な治療範囲

ADC Therapeutics Sarl :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

ADC Therapeutics Sarl :パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

ADC Therapeutics Sarl :薬剤プロファイル

  • ADCT-401
  • Monoclonal Antibody Conjugates for Prostate Cancer
  • Monoclonal Antibody Conjugates for Solid Tumor and Blood Cancer
  • VM-101
  • Monoclonal Antibody Conjugates for Cancer

ADC Therapeutics Sarl :パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

ADC Therapeutics Sarl :最新のパイプライン情報

ADC Therapeutics Sarl :開発休止中のプロジェクト

ADC Therapeutics Sarl :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08167CDB

Summary

Global Markets Direct's, 'ADC Therapeutics SA - Product Pipeline Review - 2016', provides an overview of the ADC Therapeutics SA's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ADC Therapeutics SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of ADC Therapeutics SA
  • The report provides overview of ADC Therapeutics SA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses ADC Therapeutics SA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features ADC Therapeutics SA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate ADC Therapeutics SA's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for ADC Therapeutics SA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding ADC Therapeutics SA's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ADC Therapeutics SA Snapshot
    • ADC Therapeutics SA Overview
    • Key Facts
  • ADC Therapeutics SA - Research and Development Overview
    • Key Therapeutic Areas
  • ADC Therapeutics SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ADC Therapeutics SA - Pipeline Products Glance
    • ADC Therapeutics SA - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • ADC Therapeutics SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ADC Therapeutics SA - Drug Profiles
    • ADCT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADCT-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADCT-402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADCT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADCT-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADCT-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD22 for Non Hodgkin's Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates to Target PSMA for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • ADC Therapeutics SA - Pipeline Analysis
  • ADC Therapeutics SA - Pipeline Products by Target
  • ADC Therapeutics SA - Pipeline Products by Route of Administration
  • ADC Therapeutics SA - Pipeline Products by Molecule Type
  • ADC Therapeutics SA - Pipeline Products by Mechanism of Action
  • ADC Therapeutics SA - Dormant Projects
  • ADC Therapeutics SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ADC Therapeutics SA, Key Facts
  • ADC Therapeutics SA - Pipeline by Indication, 2016
  • ADC Therapeutics SA - Pipeline by Stage of Development, 2016
  • ADC Therapeutics SA - Monotherapy Products in Pipeline, 2016
  • ADC Therapeutics SA - Phase I, 2016
  • ADC Therapeutics SA - Preclinical, 2016
  • ADC Therapeutics SA - Discovery, 2016
  • ADC Therapeutics SA - Pipeline by Target, 2016
  • ADC Therapeutics SA - Pipeline by Route of Administration, 2016
  • ADC Therapeutics SA - Pipeline by Molecule Type, 2016
  • ADC Therapeutics SA - Pipeline Products by Mechanism of Action, 2016
  • ADC Therapeutics SA - Dormant Developmental Projects,2016
  • ADC Therapeutics SA, Other Locations

List of Figures

  • ADC Therapeutics SA - Pipeline by Top 10 Indication, 2016
  • ADC Therapeutics SA - Pipeline by Stage of Development, 2016
  • ADC Therapeutics SA - Monotherapy Products in Pipeline, 2016
  • ADC Therapeutics SA - Pipeline by Target, 2016
  • ADC Therapeutics SA - Pipeline by Molecule Type, 2016
  • ADC Therapeutics SA - Pipeline Products by Mechanism of Action, 2016
Back to Top